electrophysiology in cultured rat striatal neurons and transfected HEK 293 cells. We determined that 79 53% of cultured cells endogenously expressed b3, and 94% of neurons gave tonic-level GABA-evoked currents blocked by phasic concentrations of dopamine (0.1-10 mM). Inhibition was recapitulated in HEK 293 cells transfected with a1b3, a1b3d or a1b2g2 subunits, but we instead observed potentiation in a1b3g2 and a5b3g2. Surprisingly, dopamine (1 mM) evoked rapid currents in a1b2g2, a1b3g2 and a5b3g2 in the absence of GABA. In a1b3(H267A)g2 (a1Zb3g2) receptors insensitive to trace Zn2þ inhibition, we found that other biogenic amines evoked comparatively smaller currents than DA. When the ratio of a1 was increased or we mutated a critical Zb3 tyrosine residue (Y62L), relative dopamine responses decreased. Furthermore, dopamine activity was retained but GABA activity was drastically reduced in Zb3g2 receptors, while Zb3 or g2 alone did not elicit currents. Finally, dopamine currents were picrotoxin-but not bicuculline-or gabazinesensitive. Taken together, dopamine at phasic levels is a GABAA allosteric modulator that may inhibit tonic GABA in prototypical a-containing GABAA receptors. However, at b/g-containing receptors that do not need a subunits, dopamine acts as a positive allosteric modulator. Physiology, Johns Hopkins University, Baltimore, MD, USA. GABA(A) receptors shape synaptic transmission by modulating Cl-conductance across the cell membrane. Remarkably, animal toxins that target GABA(A) receptors have not yet been identified. Here, we report the discovery of MmTX1 and MmTX2, two toxins present in Costa Rican coral snake venom that bind to GABA(A) receptors at nanomolar concentrations. Studies with recombinant and synthetic toxin variants on hippocampal neurons and cells expressing common receptor compositions suggest that MmTX1 and MmTX2 potentiate GABA(A) receptor opening and accelerate desensitization when an agonist is present. In concert, hippocampal neuron excitability measurements reveal a toxin-induced transitory network inhibition followed by an increase in spontaneous activity. Moreover, toxin injections into mouse brain result in reduced basal activity between intense seizures. Altogether, we characterized the first animal toxins that potently modulate GABA(A) receptor function, thereby establishing a novel class of tools to study this receptor family. Washington University at St. Louis, St. Louis, MO, USA. GABA-A receptors (GABA A Rs) are the target for many therapeutic drugs including benzodiazepines (BZDs), barbiturates, anesthetics and neurosteroids. These drugs bind to distinct sites and potentiate GABA-induced currents. They are often used in combination but little is known about mechanism(s) underlying their interactions. Recent crystal structures of GLIC and the glutamateactivated chloride channel suggest agonist-mediated channel opening is associated with expansion of transmembrane interfaces between M3 and M1 helices of adjacent subunits. Here, we examined if binding of different allosteric drugs and combinations of these drugs to a 1 b 2 g 2L GABA A Rs induce similar motions. We also tested whether potentiation of GABA-mediated current by pairs of drugs binding to distinct sites are additive or super-additive. We individually inserted a cysteine in the M1 helices of each GABA A R subunit at a 1 I227, b 2 L223 and g 2L I238 to monitor motions at different intersubunit interfaces. We expressed wild-type and mutant GABA A Rs in Xenopus oocytes. We measured rates of modification of the substituted cysteines in the absence and presence of different combinations of allosteric modulators that bind to different sites: the intravenous anesthetics pentobarbital (PB) and etomidate, the neurosteroid THDOC and the benzodiazepine flurazepam. When applied alone, flurazepam and THDOC induced distinct motions in the intersubunit interfaces, flurazepam increased rate of modification of only gI238C whereas THDOC only increased the rate of bL223C. When flurazepam and THDOC were co-applied, no change in rate of modification of gI238C was observed indicating that the presence of THDOC inhibited the ability of flurazepam to elicit structural rearrangements near gI238C. The data suggest structural mechanisms underlying the effects of combining drugs are different than mechanisms underlying their actions alone. ]i) and a potential therapeutic target in heart failure. Among potential interacting partners regulating NCX1 activity is the transmembrane protein phospholemman (PLM); a substrate for protein kinase A and protein kinase C. Several reports have demonstrated that binding of phosphorylated PLM (pSer68-PLM) to NCX1 leads to NCX1 inhibition, while other studies have failed to demonstrate a functional interaction of these proteins. In present study, we aimed to analyze the biological function of the pSer68-PLM-NCX1 interaction by developing anchoring disruptor peptides. We observed that PLM co-fractionated and co-immunoprecipitated with NCX1 in rat left ventricle (LV) and in co-transfected HEK293 cells. Strong binding of pSer68-PLM to one of the previously reported NCX1-QKHPD regions was demonstrated in pull-down and overlay assays. Single amino acid substitutions of native NCX1 peptide sequence 1-KHPDKEIEQLIELANYQVLS-20 revealed that single substitutions at position 1-11 (particularly with tryptophan or tyrosine) increased binding affinity of the peptide to pSer68-PLM. Interestingly, we found that double substitution at position 4 and 6 with tyrosine (D4Y and E6Y) in the native peptide sequence enhanced the binding affinity to pSer68-PLM 8-fold, compared to native sequence. The optimized peptide 1-KHPYKYIEQLIELANYQVLS-20 was further tested in a series of electrophysiological experiments using whole-cell voltage clamp technique, with voltage-ramp protocol employed to elicit NCX current. Constitutively phosphorylated (S68D) PLM was observed to inhibit NCX1 current in both forward and reverse mode. Inclusion of the disruptor peptide in the patch pipette reversed S68D-PLM inhibition of NCX1, while NCX current was not altered by a scrambled peptide control. Taken together these data strongly suggest that PLM interacts directly with NCX1, and that when PLM is phosphorylated at serine 68, the interaction inhibits NCX1 activity.
Universität des Saarlandes, Homburg, Germany, 6 Physiology, Johns Hopkins University, Baltimore, MD, USA. GABA(A) receptors shape synaptic transmission by modulating Cl-conductance across the cell membrane. Remarkably, animal toxins that target GABA(A) receptors have not yet been identified. Here, we report the discovery of MmTX1 and MmTX2, two toxins present in Costa Rican coral snake venom that bind to GABA(A) receptors at nanomolar concentrations. Studies with recombinant and synthetic toxin variants on hippocampal neurons and cells expressing common receptor compositions suggest that MmTX1 and MmTX2 potentiate GABA(A) receptor opening and accelerate desensitization when an agonist is present. In concert, hippocampal neuron excitability measurements reveal a toxin-induced transitory network inhibition followed by an increase in spontaneous activity. Moreover, toxin injections into mouse brain result in reduced basal activity between intense seizures. Altogether, we characterized the first animal toxins that potently modulate GABA(A) receptor function, thereby establishing a novel class of tools to study this receptor family. GABA-A receptors (GABA A Rs) are the target for many therapeutic drugs including benzodiazepines (BZDs), barbiturates, anesthetics and neurosteroids. These drugs bind to distinct sites and potentiate GABA-induced currents. They are often used in combination but little is known about mechanism(s) underlying their interactions. Recent crystal structures of GLIC and the glutamateactivated chloride channel suggest agonist-mediated channel opening is associated with expansion of transmembrane interfaces between M3 and M1 helices of adjacent subunits. Here, we examined if binding of different allosteric drugs and combinations of these drugs to a 1 b 2 g 2L GABA A Rs induce similar motions. We also tested whether potentiation of GABA-mediated current by pairs of drugs binding to distinct sites are additive or super-additive. We individually inserted a cysteine in the M1 helices of each GABA A R subunit at a 1 I227, b 2 L223 and g 2L I238 to monitor motions at different intersubunit interfaces. We expressed wild-type and mutant GABA A Rs in Xenopus oocytes. We measured rates of modification of the substituted cysteines in the absence and presence of different combinations of allosteric modulators that bind to different sites: the intravenous anesthetics pentobarbital (PB) and etomidate, the neurosteroid THDOC and the benzodiazepine flurazepam. When applied alone, flurazepam and THDOC induced distinct motions in the intersubunit interfaces, flurazepam increased rate of modification of only gI238C whereas THDOC only increased the rate of bL223C. When flurazepam and THDOC were co-applied, no change in rate of modification of gI238C was observed indicating that the presence of THDOC inhibited the ability of flurazepam to elicit structural rearrangements near gI238C. The data suggest structural mechanisms underlying the effects of combining drugs are different than mechanisms underlying their actions alone. ]i) and a potential therapeutic target in heart failure. Among potential interacting partners regulating NCX1 activity is the transmembrane protein phospholemman (PLM); a substrate for protein kinase A and protein kinase C. Several reports have demonstrated that binding of phosphorylated PLM (pSer68-PLM) to NCX1 leads to NCX1 inhibition, while other studies have failed to demonstrate a functional interaction of these proteins. In present study, we aimed to analyze the biological function of the pSer68-PLM-NCX1 interaction by developing anchoring disruptor peptides. We observed that PLM co-fractionated and co-immunoprecipitated with NCX1 in rat left ventricle (LV) and in co-transfected HEK293 cells. Strong binding of pSer68-PLM to one of the previously reported NCX1-QKHPD regions was demonstrated in pull-down and overlay assays. Single amino acid substitutions of native NCX1 peptide sequence 1-KHPDKEIEQLIELANYQVLS-20 revealed that single substitutions at position 1-11 (particularly with tryptophan or tyrosine) increased binding affinity of the peptide to pSer68-PLM. Interestingly, we found that double substitution at position 4 and 6 with tyrosine (D4Y and E6Y) in the native peptide sequence enhanced the binding affinity to pSer68-PLM 8-fold, compared to native sequence. The optimized peptide 1-KHPYKYIEQLIELANYQVLS-20 was further tested in a series of electrophysiological experiments using whole-cell voltage clamp technique, with voltage-ramp protocol employed to elicit NCX current. Constitutively phosphorylated (S68D) PLM was observed to inhibit NCX1 current in both forward and reverse mode. Inclusion of the disruptor peptide in the patch pipette reversed S68D-PLM inhibition of NCX1, while NCX current was not altered by a scrambled peptide control. Taken together these data strongly suggest that PLM interacts directly with NCX1, and that when PLM is phosphorylated at serine 68, the interaction inhibits NCX1 activity.
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The Talk-1 C-Terminus is a Charge-Sensitive Module Regulating Channel Activity Nicholas Vierra 1 , Prasanna K. Dadi 1 , Farah Ladak 2 , David A. Jacobson 1 . 1 Molecular Physiology & Biophysics, Vanderbilt University, Nashville, TN, USA, 2 Eastern Virginia Medical School, Norfolk, VA, USA. Human beta-cell insulin secretion is dependent on Ca 2þ entry through voltagedependent Ca 2þ channels (VDCCs). K þ channels modulate the beta-cell membrane potential, which influences VDCC activity. The most abundant K þ channel of the human islet is the two-pore domain K þ (K2P) channel TALK-1; however, its function is unknown. We characterized TALK-1 currents in primary mouse beta-cells and find that K2P currents are significantly reduced after genetic ablation of TALK-1. To identify mechanisms that regulate TALK-1 channel activity, we used a Tlþ-sensitive fluorescent screen to assess if TALK-1 is regulated by kinases. Cells expressing TALK-1 channels were monitored for changes in Tlþ flux in response to co-expression with a constitutively active kinase (examining a total of 192 kinases), revealing 9 kinases that modify Tlþ flux through TALK-1. Interestingly, three phosphatidylinositol phosphate kinases (PIKs) including PIK3CG, PI4K2B, and PIKFYVE, increased TALK-1 channel activity. To determine if activation of TALK-1 channels by PIKs is due to build-up of PIPs, we depleted membrane PIP2 with a rapamycin-recruitable phosphatase and found that TALK-1 channel activity was reduced. As charged residues of other K þ channels mediate PIP2 sensitivity, we assessed if PIP2 influences TALK-1 channel activity through a charged residue enriched domain in the C-terminus. We found that neutralization of these charged residues significantly reduced PIP2 activation of TALK-1 channels. Importantly, PIP2 introduced via patch pipette into primary mouse beta-cells also significantly enhanced TALK-1 currents. As glucose induces Ca 2þ -dependent oscillations in beta-cell PIP2, we then assessed how TALK-1 regulates islet Ca 2þ dynamics. We find that Ca 2þ oscillation frequency is significantly increased in islets lacking TALK-1, which 434a Tuesday, February 10, 2015 
